Literature DB >> 6787169

Post-transfusion hepatitis: antigen/antibody systems correlated with non-A, non-B hepatitis.

L V Chircu, M Pezzella, V Lacava, G Ricci.   

Abstract

In seven patients post-transfusion hepatitis (PTH) was due to non-A, non-B virus(es) (38.9% of all PTH, while 61.1% were due to hepatitis B virus (HBV). No clinical or biochemical differences were observed in non-A, non-B PTH when compared with PTH due to HBV, while incubation period was very ample, from 15 days to nine months (generally 45 days to two months). An antigen/antibody system was shared by five of our patients (their sera showed precipitin lines when assayed by immunodiffusion with known sources of antigen or antibody), while in one patient an antigen/antibody system was detected when onset serum was assayed with self-recovery serum but not when assayed with known sources of antigen and antibodies, nor with sera of the other five patients. Antigen was detected during the first weeks of illness, antibody at recovery, for both systems. The results suggest that there may be at least two antigen/antibody systems correlated to non-A, non-B hepatitis not necessarily linked to incubation period.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6787169     DOI: 10.1002/jmv.1890060207

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  3 in total

1.  Immune response to purified non-A, non-B hepatitis-related antigen demonstrated by leukocyte migration inhibition in patients recovering from the infection.

Authors:  A Nicole; O Spertini; D Lavanchy; P C Frei
Journal:  Infection       Date:  1986 Jan-Feb       Impact factor: 3.553

2.  [Hepatitis non-A, non-B: epidemiologic, clinical, serologic and morphologic aspects].

Authors:  H P Spichtin
Journal:  Klin Wochenschr       Date:  1985-05-02

3.  Detection of non-A, non-B hepatitis antigen by immunocytochemical staining.

Authors:  K H Burk; P E Oefinger; G R Dreesman
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.